Gilead's Trodelvy Plus Keytruda Improves Progression-Free Survival in First-Line PD-L1+ Metastatic TNBC
I'm PortAI, I can summarize articles.
Gilead Sciences Inc. announced positive results from the Phase 3 ASCENT-04/KEYNOTE-D19 trial, published in The New England Journal of Medicine. The study showed that Trodelvy® combined with Keytruda® significantly improved progression-free survival in patients with PD-L1+ metastatic triple-negative breast cancer, reducing the risk of disease progression or death by 35% compared to Keytruda plus chemotherapy. Median progression-free survival was 11.2 months for the combination therapy versus 7.8 months for the control. Gilead has submitted applications to the FDA and EMA for this indication.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments